Prognosis of ALF of unknown cause: results of the French multicentre prospective HASIPRO study

Archive ouverte

Coilly, A. | Dharancy, S. | Duvoux, C. | Martino, V.D. | Dumortier, Jérôme | Radenne, S. | Alric, Laurent | Besch, C. | Francoz, C. | Perarnaud, J. | Rudler, M. | Carbonell, N. | Silvain, C. | Leroy, V. | Pichard, A.V. | Lassailly, G. | Artru, F. | Antonini, T. | Agostini, H. | Piedvache, C. | Duclos-Vallée, J.-C. | Ichai, P. | Samuel, D.

Edité par CCSD ; Elsevier -

International audience. Acute liver failure (ALF) of unknown causerepresents between 10% to 50% of ALF, worldwide. Their prognosis ispoorercompared tothosewhen acause is identified. To date,no studyhas specifically focused on the prognosis of these patients. The mainobjective was to determine the factors associated with livertransplantation (LT)-free survival at 3 months.

Consulter en ligne

Suggestions

Du même auteur

Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation results from the CO23 ANRS CUPILT study

Archive ouverte | Dumortier, Jerome | CCSD

International audience. Recurrence of hepatitis C virus (HCV) after liver transplantation (LT) can rapidly lead to liver graft cirrhosis and, therefore, graft failure and retransplantation or death. The aim of the p...

Safety of sofosbuvir-based regimens after liver transplantation longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

Archive ouverte | Anty, R. | CCSD

International audience. Background In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir-based regimens. Changes in serum creatinine or in the estimated ...

Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study

Archive ouverte | Houssel-Debry, P. | CCSD

International audience. EASL International Liver Congress, APR 13-17, 2016, Barcelona, SPAIN

Chargement des enrichissements...